Chronic Bronchitis
Conditions
Keywords
Disease Exacerbation, Acute Exacerbations of Chronic Bronchitis, AECB, Avelox, Bronchitis
Brief summary
In this study data of patients with moderate or severe acute exacerbations of chronic bronchitis (AECB) were collected. There were two different cohorts which were compared (Moxifloxacin and other antibiotics) concerning effectiveness and tolerance. It was a prospective study which was accomplished in 100 ambulatory practice offices.
Detailed description
The study design was slightly changed to adapt the target population. Due to these changes the study was restarted on 8th December 2009.
Interventions
Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Acute exacerbation of chronic bronchitis from Anthonisen type I or II * FEV1 of \< 50 % * Patient must be ensured in the statutory health insurance * Further contraindications of the prescribed pharmaceutical products must be considered
Exclusion criteria
* Patients who change from one cohort to the other
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effectiveness and tolerance of/to the different therapies | within the first 14 days |
| Possible hospitalisation rate | within the first 14 days |
Countries
Germany
Outcome results
None listed